News & Events

We are proud to announce that Redbiotec has been voted 13th out of all Swiss start-up companies founded since 2006. The ranking is based on the evaluation of 100 Experts in the start-up scene. Start-up companies from all sectors (incl. IT, Cleantech and others) were evaluated. For further information, please see http://www.startup.ch.

Redbiotec is pleased to announce that it has entered into collaboration with Merck Sharp & Dohme Corp. (NJ, USA), in which it will apply its proprietary technology platform rePAX® to an undisclosed discovery area.

Redbiotec CEO Christian Schaub has been invited to participate in the panel discussion at the Biotech Connect Day September 22 in the BioValley LifeSciences Week 2011. The BioValley Life Sciences Week is the annual networking platform for the regional Life Sciences Community in the trinational Basel area.

Redbiotec has entered into a perennial collaboration agreement with an undisclosed large pharmaceutical company. Under the contract, Redbiotec will manufacture and re-supply a relevant viral protein complex using the rePAX® technology.

Christian Schaub, CEO of Redbiotec, is very pleased about this development: “This contract reflects our existing good partnership and the unique capabilities of Redbiotec in the development and manufacturing of designer VLPs and protein complexes”. Redbiotec develops prophylactic vaccines in the area of CMV (Cytomegalovirus), HPV and Influenza and provides customized solutions in biologics.

Mrs Nila-Pia Raehle, formerly working for Ypsomed and Synthes, was hired in order to strengthen Redbiotec’s business development. Nila has over 10 years experience in product management and deal making with pharma companies.